Funds advised by BC Partners (BC Partners), a leading international private equity firm, have reached an agreement to acquire a majority stake in Synthon International Holding B.V. (Synthon or the Company), a global market leader in the development of complex Generics, from its parent company Synthon Holding B.V. (the Parent). BC Partners will partner with Synthon’s founder Dr. Jacques Lemmens, who will remain a shareholder in the Company. The Company will be carved out from the Parent and continue to operate under the Synthon brand. The transaction is subject to regulatory approvals and is expected to close in the coming months. Additional terms of the transaction were not disclosed.
Synthon focuses on developing, manufacturing and out-licensing complex generics and hybrid medicines for patients around the world. It was founded by Dr. Jacques Lemmens in 1991 and has since developed a diversified base of over 200 customers serving around 100 countries worldwide.
Latham & Watkins represented BC Partners in the transaction with a team led by London corporate partners Robbie McLaren and Huw Thomas, with associates Muli Zhou and James Freeland. Advice was also provided by London partner Fiona Maclean on the transitional services, associate Frances Stocks Allen on regulatory and pharmaceutical supply chain issues, and by partner Karl Mah on tax matters.